US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Denali Therapeutics Inc.
< Previous
1
2
Next >
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
August 06, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
July 27, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier
July 09, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
June 18, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
May 21, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
BIIB
DNLI
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
May 07, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
April 03, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
March 25, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
February 26, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
February 05, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
February 02, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™
January 29, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome
January 06, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
December 30, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
December 10, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
December 09, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
December 04, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
RPRX
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
November 06, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces Board and Executive Leadership Updates
November 06, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
October 13, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
August 11, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
July 07, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
May 06, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
April 02, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
February 27, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
February 06, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
January 30, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
January 13, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
January 08, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
January 06, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Tickers
DNLI
< Previous
1
2
Next >
